Precigen Receives FDA Clearance Of IND To Initiate Phase 2 Study Of PRGN-2009 Off-The-Shelf AdenoVerse Immunotherapy In Combination With Pembrolizumab To Treat Patients With Recurrent Or Metastatic Cervical Cancer
Portfolio Pulse from Benzinga Newsdesk
Precigen has received FDA clearance to initiate a Phase 2 study of PRGN-2009, an off-the-shelf AdenoVerse immunotherapy, in combination with pembrolizumab for the treatment of recurrent or metastatic cervical cancer.
May 31, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's FDA clearance for the Phase 2 study of PRGN-2009 may positively impact the company's stock price.
The FDA clearance for the Phase 2 study of PRGN-2009 is a significant milestone for Precigen, as it allows the company to advance its immunotherapy product for the treatment of cervical cancer. This positive development may lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100